Outlook Therapeutics, Inc. Long Term Debt

• Outlook Therapeutics, Inc. showed a decrease of -48.9% in Long Term Debt from 2018 to 2019.
• This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2019.
• XBRL data for this metric is available from 2015 to 2019 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2015: $2.92 million | Q1 2016: $2.55 million | Q2 2016: $2.37 million | Q4 2016: $191.2 thousand | Q1 2017: $178.3 thousand | Q2 2017: $165.0 thousand | Q4 2017: $143.5 thousand | Q1 2018: $127.8 thousand | Q2 2018: $111.5 thousand | Q4 2018: $86.9 thousand | Q1 2019: $75.1 thousand | Q2 2019: $62.9 thousand.
• Over the full 5 years of available data (2015 to 2019), Outlook Therapeutics, Inc.'s Long Term Debt has declined by 98.3%.
• Historical annual values: Fiscal year 2019: $50.3 thousand | Fiscal year 2018: $98.5 thousand | Fiscal year 2017: $151.1 thousand | Fiscal year 2016: $2.23 million | Fiscal year 2015: $2.92 million.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026